4.7 Article

Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations

Journal

BLOOD
Volume 138, Issue 24, Pages 2589-2592

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2021012315

Keywords

-

Categories

Funding

  1. Pharmacyclics (an AbbVie company)
  2. CLL Global Research Foundation
  3. National Institutes of Health, National Cancer Institute [CA016672]

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available